Watch out for him, he is slick! Lesson learned already! I'm on the sidelines just waiting! Best to you!
Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
Sentiment: Strong Buy
Medican Enterprises Inc. (MDCN), announced today that the 67,000 square foot facility located, in Phoenix Arizona, it is acquiring has received zoning approval and is now zone compliant for the operation of legal #$%$ businesses.
“With the zoning approval in hand, this commercial transaction now meets our criteria and we are moving rapidly to finalize the due diligence process,” commented Ken Williams, CEO of Medican Enterprises. “Located just minutes from Hwy 60 and the I-17 and featuring excellent visibility in a high traffic center, this unique property represents the type of asset we are looking for.”
The transaction is planned for closure by the end of the first quarter of 2015.
Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
SAN FRANCISCO and GENEVA, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that its abstract titled, "The LymPro® Assay: A Biomarker For Alzheimer's Disease Using Blood Samples From Clinically Diagnosed Alzheimer's Disease And Cognitively Intact Subjects," was accepted for poster presentation at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.
The poster will highlight the positive data analysis of whole blood samples from 140 subjects (71 Alzheimer's disease and 69 age matched controls) using the company's LymPro Test blood-based assay for Alzheimer's disease (AD). The LymPro Test measures lymphocyte proliferation in response to a mitogenic stimulus and quantifies the extent to which lymphocytes have entered the cell division cycle. Cell cycle dysregulation in neurons is a key pathology in AD, that results in neuronal death and cognitive decline. In the LymPro test, lymphocyte measurements are used as a surrogate for this neuronal cell dysfunction. The analysis demonstrates that, in combination with standard of care clinical measurements, LymPro can give physicians greater confidence that an Alzheimer's diagnosis is truly accurate.
"We are very pleased to have this confirmatory LymPro abstract accepted for a poster session at one of the premiere scientific congresses focused on neurological disorders," said Gerald E. Commissiong, President & CEO of Amarantus BioSciences Holdings, Inc. "We believe the LymPro Test is an important leading Alzheimer's biomarker assay and is a key diagnostic asset for advancing robust therapeutic clinical studies in Alzheimer's disease. This conference will provide important exposure as we continue building a significant customer base for blood-based biomarker services in Alzheimer's disease, with the ultimate shared goal of improving the current standard of care used to treat AD."
The poster data to be presented at AD/PD 2015 by Louis Kirby, Corporate Advisor and Medical Director of Amarantus Diagnostics, confirms the consistent and accurate ability of the LymPro Test to distinguish univariate and multivariate combination indicators of lymphocyte proliferation AD biomarkers from controls. Additionally, the analysis corroborates two previous peer-reviewed publications in which data from the Company's recently completed LP-002 clinical study established the LymPro Test as an advantageous diagnostic that can serve as the first step in a multistep diagnostic process for early identification of Alzheimer's disease.
Sentiment: Strong Buy
I will check them out, st is stock twits. I f I like a stock I will go on there and check out some of the commentary....it is still picking and choosing however. Some individuals are worht following. I was invested in a bio tech, followed the company on Stock Twits and managed to block over 7 pages worth of folks! LOL! I will continue to delve into all the leads you gave me. As I said before, I still have some time to decide. Thank you for all your help. I'll check ya out on twtr. Nick
William, do you mind if I pick your brain one more time? What are your viewpoints both negative and positive for $OIL? Seems to be in a good position for investment purposes.Also if you are on twtr or ST let me know. I would follow ya. Have a great day! Many thanks!